Hanmi Pharm: back-to-back technology export deals overshadow management dispute with strong core business
Predicted impact: Medium
Fabry drug export worth about 38% of revenue was already reported recently.
Hanmi Pharm한미약품
128940 · KOSPI · ₩128940 · 한미약품
₩415,000▲ ₩26,500 (6.82%)End-of-day · Oct 30, 2026 · End-of-day prices.
Price · 1Y +6.27%
- Market cap
- ₩5.3T
- Enterprise value
- ₩5.2T
- P/E
- 24.5×
- P/B
- 3.8×
- Dividend yield
- 0.5%
- ROE
- 15.5%
- Net margin
- 13.1%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−35.9% from the high
₩302,000Today: ₩397,000 – ₩421,500₩647,000
Returns
- 1W+14.8%
- 1M−16.8%
- 3M+24.4%
- 6M−9.8%
- YTD−8.2%
- 1Y+6.3%
- Volume today
- 249,822
- 2.2× the 20-day average
- Traded today
- ₩103B
- Listed shares
- 12,810,991
- EPS (12 months)
- ₩16,942
- Earnings yield 4.1%
AI research · Update noteHanmi Pharm Q3 2026 Preliminary Results: Operating Profit Falls 31.3% Year on YearThe Q3 result is a clear negative for the earnings-improvement story: profit fell sharply while revenue grew modestly, and the cause is not given.Read the full report →
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Why is it moving?
+6.8% on Oct 30, 2026. Trading value 2.1× its normal.
Hanmi Pharm signed a technology export deal with US firm BioMarin for a Fabry disease drug, reported as worth up to $475 million, and the stock rose sharply on the news. Coverage also notes a management dispute that has been weighing on the company.
AI summary of the news and filings linked. It can be wrong; check them.
- Hanmi Pharm: back-to-back technology export deals overshadow management dispute with strong core business (Money Today)
- GC Biopharma, Hanmi Pharm strike $475m Fabry disease drug deal with BioMarin (The Korea Herald)
- [Stocks in Focus] Hanmi Pharm surges 8%+ on Fabry disease new drug tech export and obesity drug hopes (Etoday)
- GC Biopharma and Hanmi Pharm sign ₩634.7B technology export of Fabry disease drug to US's BioMarin, expanding K-pharma's reach (Herald Business)
- • Filing: Investor relations (IR) event
- • Filing: Major management matter relevant to investors
- • Kyobo Securities cut its target to ₩600,000 (from ₩700,000)
- • Mirae Asset Securities started coverage with a target of ₩700,000
- • Foreign investors sold a net ₩28B that day
- • Buzz 49 on JONBUR: heavy trading
Possible reasons, not certainties. Not financial advice.
Signals
Normal- BuzzNormalBuzz 49: heavy trading.
- SentimentPositiveNews: A large overseas licensing deal outweighs a management dispute in the headlines. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-18.1% over the last month; the price is below its 20-day average.
- News impactHigh41 news items and filings in two weeks; 2 rated high impact, 22 medium.
- StreetTargets going down3 brokers, average target 61% from the price; last 30 days: 0 raised, 1 cut.
Signals describe activity, not recommendations. Not financial advice.
Leveraged ETF flows
Estimated leveraged-ETF rebalance on Oct 30: sell ₩909M at the close (1.9% of 20-day average trading value)
On its 24 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 1.2% of trading value and pointed the same way 10 of 24 times.
- 2× KODEX Leverage −₩440M
- -2× KODEX 200 Futures Inverse 2X −₩290M
- -1× KODEX Inverse −₩68M
- 2× TIGER 200IT Leverage −₩34M
- 2× TIGER Leverage −₩34M
Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.
Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.
Estimate based on ETF size and daily moves; actual trades may differ.
ETFs holding this
All ETFs →Held by 32 funds.
- TREX 2000.1%
- WON 2000.1%
- ACE 2000.1%
- ACE 200 TR0.1%
- ACE Leverage2×0.1%
- DAISHIN K2000.1%
- FOCUS 2000.1%
- HANARO 2000.1%
Estimated from the funds' index or underlying stock.
Futures and options
All stock futures →Futures (2026-11): 416,500
Basis +0.36% · implied rate +10.1%
Open interest 11,234 contracts
Futures and options can lose more than you put in. Figures describe the market; they are not predictions or recommendations. Paper trading only.
Hanmi Pharm stock overview
Hanmi Pharm (한미약품, KRX: 128940) is listed on KOSPI, in the Biotech & Pharma sector. Hanmi Pharmaceutical manufactures and sells pharmaceuticals through three segments: pharmaceuticals, active pharmaceutical ingredients (APIs), and overseas pharmaceuticals. Its shares closed at ₩415,000 on Oct 30, 2026, up 6.82% on the day, giving it a market value of ₩5.3T.
Key facts
- Market cap
- ₩5.3T
- Sector
- Biotech & Pharma
- Latest price change
- +6.82%
- As of
- Oct 30, 2026
- Main business
- Hanmi Pharmaceutical manufactures and sells pharmaceuticals through three segments: pharmaceuticals, active pharmaceutical ingredients (APIs), and overseas pharmaceuticals.
Quick answers about Hanmi Pharm
- What does Hanmi Pharm do?
- Hanmi Pharmaceutical manufactures and sells pharmaceuticals through three segments: pharmaceuticals, active pharmaceutical ingredients (APIs), and overseas pharmaceuticals. Its main products include the hypertension combination drug Amosartan, the lipid-lowering drug Rosuzet, the reflux esophagitis treatment Esomezol, and the erectile dysfunction drug Palpal, and it focuses on R&D for innovative new drugs. Hanmi Fine Chemical supplies APIs, especially cephalosporin antibiotics, to multinational pharmaceutical companies and exports to about 40 countries, while Beijing Hanmi Pharmaceutical sells children's and adult digestive remedies and cough medicines in China.
- What is the market cap of Hanmi Pharm?
- The market capitalisation of Hanmi Pharm was ₩5.3T at the close on Oct 30, 2026.
- What is the analyst target price for Hanmi Pharm?
- The average target price of 3 brokers covering Hanmi Pharm is ₩666,667 (range ₩600,000 to ₩700,000), 60.6% above versus the latest price, based on each broker's latest public report within six months.
- Who are the largest shareholders of Hanmi Pharm?
- According to the latest official filings, the largest reported holders are Hanmi Science (49.55%, as of Sep 29, 2026); National Pension Service (10.15%, as of Oct 6, 2026); VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND (0.71%, as of Jul 31, 2026).
- When is the next earnings report from Hanmi Pharm?
- Korean companies rarely announce results dates in advance. Based on when Hanmi Pharm filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Hanmi Pharm?
- Yes. The National Pension Service held 9.61% of Hanmi Pharm shares as of Oct 2, 2026.
Company profile
Hanmi Pharmaceutical manufactures and sells pharmaceuticals through three segments: pharmaceuticals, active pharmaceutical ingredients (APIs), and overseas pharmaceuticals. Its main products include the hypertension combination drug Amosartan, the lipid-lowering drug Rosuzet, the reflux esophagitis treatment Esomezol, and the erectile dysfunction drug Palpal, and it focuses on R&D for innovative new drugs. Hanmi Fine Chemical supplies APIs, especially cephalosporin antibiotics, to multinational pharmaceutical companies and exports to about 40 countries, while Beijing Hanmi Pharmaceutical sells children's and adult digestive remedies and cough medicines in China.
Written by AI from the company's latest annual report.
- Korean name
- 한미약품
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)Contract drug manufacturing (CDMO)Obesity drugsADC & cancer drugsPharmaceuticals
- CEO
- 황상연
- Founded
- Jul 2010
- Listed
- Jul 2010
- Listed shares
- 12,810,991
- Fiscal year ends
- Month 12
- Website
- -
Similar companies
- Samsung Biologics207940 · ₩69T₩1,487,000+8.86%
- Celltrion068270 · ₩44T₩191,600+1.22%
- Alteogen196170 · ₩15T₩211,500−3.86%
- SK biopharmaceuticals326030 · ₩6.1T₩77,700−0.13%
- Yuhan000100 · ₩5.5T₩75,100+0.54%
- HLB028300 · ₩5.3T₩40,000+0.76%
- SAM Chun Dang Pharm000250 · ₩4.3T₩182,700−3.13%
- SK Bioscience302440 · ₩2.6T₩32,750+1.71%
Recent news
GC Biopharma, Hanmi Pharm strike $475m Fabry disease drug deal with BioMarin
Predicted impact: Medium
$475m Fabry deal shared with Hanmi; already reported in recent days, and size is modest versus revenue.
[Stock of the Day] GC Genome, a Genetic Analysis Play, and Hanmi Pharm, Maker of a Domestic Obesity Drug, in Focus
Predicted impact: Low
Daily stock-pick mention with no company-specific facts or sizes given.
Recent filings
See all- Investor relations (IR) eventOct 30, 2026
- Major management matter relevant to investorsOct 30, 2026
- Share cancellation decisionOct 27, 2026
- Preliminary earnings (consolidated)Oct 27, 2026
- Investor relations (IR) eventOct 16, 2026
Titles in Korean until English translations are added.
Creators talking about this
Also known as: Hanmi Pharm / 한미약품 / 128940 / KRX:128940
Source: KRX statistical information